06 March 2020
Visiongain has launched a new pharma report Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.
The gene therapy market is in early stages of its development, this new Visiongain report analyses the emerging gene therapy market, a field holding great technological and commercial potential. Gene therapy is no longer a treatment solely for rare diseases but has expanded its targets and can now be applied to cancer, cardiovascular diseases, diabetes and more. We have already seen gene therapies launched in recent years and are likely to see upcoming launches due to rapid advancement and the number of clinical trials in this field. Gene therapy has seen many advances in recent years, particularly with vector technology, with AAV and lentiviral vectors showing much potential.
The lead analyst of the report commented "The growth of the overall gene therapy market will be primarily driven by growth in the cardiovascular and rare diseases sector. Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets. The market still faces substantial challenges related to ethics, pricing and scalability. Companies looking to market their products optimally should also be developing companion diagnostics for predictive biomarker testing, to market alongside their gene therapies. These companies will also need to agree on creating reimbursements models that will convince health care providers to invest in these novel therapies."
Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Pfizer, Novartis & GSK.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.
01 December 2022
The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.
01 December 2022
The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.
30 November 2022
The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.